Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share
-
Shares outstanding
-
41.1M
-
Number of holders
-
21
-
Total 13F shares, excl. options
-
27.1M
-
Shares change
-
+565K
-
Total reported value, excl. options
-
$68.3M
-
Value change
-
+$1.41M
-
Number of buys
-
8
-
Number of sells
-
-6
-
Price
-
$2.52
Significant Holders of Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) as of Q2 2022
22 filings reported holding ACHL - Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share as of Q2 2022.
Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) has 21 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.1M shares
of 41.1M outstanding shares and own 65.95% of the company stock.
Largest 10 shareholders include Syncona Portfolio Ltd (11.1M shares), RA CAPITAL MANAGEMENT, L.P. (5.01M shares), BAKER BROS. ADVISORS LP (2.59M shares), Artal Group S.A. (2.26M shares), Point72 Asset Management, L.P. (1.78M shares), Redmile Group, LLC (1.61M shares), ORBIMED ADVISORS LLC (1.58M shares), AXA S.A. (284K shares), BlackRock Inc. (260K shares), and KETTLE HILL CAPITAL MANAGEMENT, LLC (243K shares).
This table shows the top 21 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.